The Life Sciences team advised Fresenius Medical Care as it entered into a strategic, global partnership with Humacyte. Fresenius Medical Care will make a $150 million equity investment in Humacyte to gain a 19% fully diluted ownership stake in the company and will obtain the exclusive global rights to commercialize Humacyte’s investigational human acellular vessel, HUMACYL.
With the investment, Fresenius Medical Care will have the opportunity to bring transformative clinical innovation in the form of Humacyte’s bioengineered human acellular vessels to the worldwide end stage renal disease (ESRD) patient population following product approval. The transaction is subject to customary closing conditions and is expected to close in July 2018.
Fresenius Medical Care is the world’s largest provider of products and services for individuals with renal diseases of which around 3.2 million patients worldwide regularly undergo dialysis treatment.
For additional details on the partnership, please read the press release.